Received Mar 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | MZ47A | — |
adult patient was administered with a pediatric dose of Havrix; underdose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 58-year-old female patient who received HAV (Havrix pediatric) (batch number MZ47A, expiry date 24-APR-2026) for prophylaxis. On 23-FEB-2026, the patient received the 1st dose of Havrix pediatric. On 23-FEB-2026, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: adult patient was administered with a pediatric dose of Havrix) and underdose (Verbatim: underdose). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 10-MAR-2026 The reporter wanted to know whether a second pediatric dose had been needed to complete the adult dose.